Search results
Duchenne approval exposes FDA rift over Sarepta gene therapy
BioPharma Dive via Yahoo Finance· 2 days agoPeter Marks’ decision to override the objections of agency staff and broaden use of Elevidys could...
FDA places partial clinical hold on Zentalis’ trials of azenosertib for cancer
Clinical Trials Arena via Yahoo Finance· 4 days agoIn clinical trials to date, azenosertib has demonstrated a good tolerance profile and shown...
Sarepta Therapeutics surges 36% after-hours following expanded FDA approval
Investing.com· 3 days agoSarepta Therapeutics surges 36% after-hours following expanded FDA approval
FDA Escapes Accountability for Removing Abortion Drug Safeguards—for Now
Newsweek· 2 days agoEvery so often, however, the Supreme Court will momentarily steal the spotlight with a...
FDA Authorizes First Menthol E-Cigarettes
MedPage Today· 2 days agoThe FDA on Friday authorized marketing of four menthol-flavored e-cigarette products even as the Biden administration continues to drag its heels on...
Sarepta’s Duchenne gene therapy wins expanded FDA approval - Boston Business Journal
The Business Journals· 2 days agoThe FDA has expanded its previous approval for Sarepta Therapeutics’ gene therapy to treat Duchenne...
One Big, Unintended Consequence of the Failed Attempt to Ban the Abortion Pill
Slate via Yahoo News· 5 days agoThe best way to support our work is by joining Slate Plus. (If you are already a member, consider a...
FDA Expands Approval of Sarepta Therapeutics’ Elevidys for the Treatment of Duchenne Muscular...
Pharmaceutical Executive Magazine· 2 days agoThe FDA has expanded its approval of Sarepta Therapeutics’ Elevidys (delandistrogene moxeparvovec),...
The Unhealthiest Pre-Packaged Frozen Meatballs You Can Buy
Mashed via Yahoo News· 4 hours agoThat's equivalent to 28% of the FDA's daily recommended value -- and it's coupled with a quantity of...
The Price of Perky Boobs
Allure via Yahoo News· 4 days ago...controversial topic—it’s a term patients came up with, rather than a medical diagnosis; there’s a lack of data on the topic; and no real agreement...
